NO933077L - Anvendelse av IL-4-reseptor for terapi i profylakse og diagnostikk av allergiske, virale og parasitiske og bakterielle sykdommer - Google Patents

Anvendelse av IL-4-reseptor for terapi i profylakse og diagnostikk av allergiske, virale og parasitiske og bakterielle sykdommer

Info

Publication number
NO933077L
NO933077L NO933077A NO933077A NO933077L NO 933077 L NO933077 L NO 933077L NO 933077 A NO933077 A NO 933077A NO 933077 A NO933077 A NO 933077A NO 933077 L NO933077 L NO 933077L
Authority
NO
Norway
Prior art keywords
prophylaxis
allergic
parasitic
viral
diagnosis
Prior art date
Application number
NO933077A
Other languages
English (en)
Other versions
NO312336B1 (no
NO933077D0 (no
Inventor
Karlheinz Enssle
Roland Kurrle
Leander Lauffer
Friedrich-Robert Seiler
Original Assignee
Behringwerke Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Behringwerke Ag filed Critical Behringwerke Ag
Publication of NO933077D0 publication Critical patent/NO933077D0/no
Publication of NO933077L publication Critical patent/NO933077L/no
Publication of NO312336B1 publication Critical patent/NO312336B1/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D53/00—Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases, aerosols
    • B01D53/34—Chemical or biological purification of waste gases
    • B01D53/46—Removing components of defined structure
    • B01D53/48—Sulfur compounds
    • B01D53/50—Sulfur oxides
    • B01D53/501—Sulfur oxides by treating the gases with a solution or a suspension of an alkali or earth-alkali or ammonium compound
    • B01D53/502—Sulfur oxides by treating the gases with a solution or a suspension of an alkali or earth-alkali or ammonium compound characterised by a specific solution or suspension
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56905—Protozoa
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56961—Plant cells or fungi
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Environmental & Geological Engineering (AREA)
  • Botany (AREA)
NO19933077A 1992-08-31 1993-08-30 Anvendelse av IL-4-reseptor for produksjon av et diagnostisk hjelpemiddel og et farmasöytisk preparat for terapi og profylakseav infeksjoner NO312336B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4228941 1992-08-31
DE4322330A DE4322330A1 (de) 1992-08-31 1993-07-05 Verwendung des IL-4-Rezeptors zur Therapie, Prophylaxe und Diagnose von allergischen, viralen, parasitären und bakteriellen Erkrankungen sowie von Pilzinfektionen

Publications (3)

Publication Number Publication Date
NO933077D0 NO933077D0 (no) 1993-08-30
NO933077L true NO933077L (no) 1994-03-01
NO312336B1 NO312336B1 (no) 2002-04-29

Family

ID=25918065

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19933077A NO312336B1 (no) 1992-08-31 1993-08-30 Anvendelse av IL-4-reseptor for produksjon av et diagnostisk hjelpemiddel og et farmasöytisk preparat for terapi og profylakseav infeksjoner

Country Status (15)

Country Link
US (2) US6210661B1 (no)
EP (1) EP0585681B1 (no)
JP (1) JP3703103B2 (no)
AT (1) ATE202285T1 (no)
AU (1) AU668974B2 (no)
CA (1) CA2105101C (no)
DE (2) DE4322330A1 (no)
DK (1) DK0585681T3 (no)
ES (1) ES2158852T3 (no)
GR (1) GR3036655T3 (no)
IL (1) IL106842A (no)
MX (1) MX9305269A (no)
NO (1) NO312336B1 (no)
NZ (1) NZ248516A (no)
PT (1) PT585681E (no)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
DE4322330A1 (de) * 1992-08-31 1994-03-03 Behringwerke Ag Verwendung des IL-4-Rezeptors zur Therapie, Prophylaxe und Diagnose von allergischen, viralen, parasitären und bakteriellen Erkrankungen sowie von Pilzinfektionen
US20030059428A1 (en) * 1993-02-26 2003-03-27 Boris Skurkovich Treatment of autoimmune diseases
AU1059095A (en) * 1993-11-24 1995-06-13 Australian National University, The Treatment of viral disease with cd40l peptide
ATE309267T1 (de) 1994-04-28 2005-11-15 Boehringer Ingelheim Pharma Methode zur proliferation und differenzierung von b-zellen und verwendungen dafür
DE4444260A1 (de) * 1994-12-13 1996-06-20 Hoechst Ag Cyclohexapeptide und deren Mischungen, Verfahren zur Herstellung sowie deren Verwendung
CN1058638C (zh) * 1995-06-27 2000-11-22 中国药品生物制品检定所 胞内分枝杆菌变态反应原提取方法
US6080719A (en) * 1996-02-23 2000-06-27 Hoechst Aktiengesellschaft Cyclohexapeptides and their mixtures, a process for preparing them, and their use
US5958671A (en) * 1996-04-23 1999-09-28 Presidents And Fellows Of Harvard College Methods and compositions for regulating T cell subsets by modulating transcription factor activity
US6537810B1 (en) 1996-04-23 2003-03-25 President And Fellows Of Harvard College Methods for regulating T cell subsets by modulating transcription factor activity
US6703488B1 (en) * 1998-01-15 2004-03-09 Center For Molecular Medicine And Immunology Antibody/receptor targeting moiety for enhanced delivery of armed ligand
US7083949B2 (en) * 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
WO2002055101A2 (en) * 2000-12-21 2002-07-18 Inhale Therapeutic Syst Storage stable powder compositions of interleukin-4 receptor
KR100453877B1 (ko) * 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
US20030144193A1 (en) * 2001-12-20 2003-07-31 Rottman James B. TANGO 197 and TANGO 216 compositions and methods
WO2003092610A2 (en) 2002-05-01 2003-11-13 Regeneron Pharmaceuticals, Inc. Methods of using cytokine antagonists to treat hiv infection and aids
US8425926B2 (en) * 2003-07-16 2013-04-23 Yongxing Qiu Antimicrobial medical devices
US7294353B2 (en) * 2003-10-24 2007-11-13 Herbalscience, Llc Methods and compositions comprising ilex
EP1767216B1 (en) 2004-06-11 2012-07-11 Riken Drug having regulatory cell ligand contained in liposome
WO2011132086A2 (en) 2010-04-21 2011-10-27 MeMed Diagnostics, Ltd. Signatures and determinants for distinguishing between a bacterial and viral infection and methods of use thereof
US9018006B2 (en) 2010-07-23 2015-04-28 The University Of Toledo Stable Tregs and related materials and methods
AU2013217935B2 (en) 2012-02-09 2018-05-17 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections and methods of use thereof
RU2730836C2 (ru) 2014-08-14 2020-08-26 Мемед Диагностикс Лтд. Вычислительный анализ биологических данных с применением многообразия и гиперплоскости
US20170234873A1 (en) 2014-10-14 2017-08-17 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections in non-human subjects and methods of use thereof
EP3230740B1 (en) 2014-12-11 2025-05-21 Memed Diagnostics Ltd. Marker combinations for diagnosing infections and methods of use thereof
CA3015046A1 (en) 2016-03-03 2017-09-08 Memed Diagnostics Ltd. Rna determinants for distinguishing between bacterial and viral infections
WO2017149547A1 (en) 2016-03-03 2017-09-08 Memed Diagnostics Ltd. Analyzing rna for diagnosing infection type
WO2018011796A1 (en) 2016-07-10 2018-01-18 Memed Diagnostics Ltd. Early diagnosis of infections
WO2018011795A1 (en) 2016-07-10 2018-01-18 Memed Diagnostics Ltd. Protein signatures for distinguishing between bacterial and viral infections
WO2018060998A1 (en) 2016-09-29 2018-04-05 Memed Diagnostics Ltd. Methods of prognosis and treatment
WO2018060999A1 (en) 2016-09-29 2018-04-05 Memed Diagnostics Ltd. Methods of risk assessment and disease classification
US10209260B2 (en) 2017-07-05 2019-02-19 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections and methods of use thereof
CN113402589A (zh) * 2021-06-18 2021-09-17 苏州工业园区唯可达生物科技有限公司 一种提高抗体产量的信号肽

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3806617A1 (de) 1988-03-02 1989-09-14 Behringwerke Ag Erzeugung hochexprimierender, rekombinanter, eukaryotischer zellen
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
CA2035868A1 (en) * 1989-07-06 1991-01-07 Richard C. Svrluga Hybrid molecules
AU641941B2 (en) * 1989-09-07 1993-10-07 Schering Corporation Interleukin-4 receptors
EP0464533B1 (de) 1990-06-28 1998-07-29 Hoechst Aktiengesellschaft Fusionsproteine mit immunglobulinanteilen, ihre Herstellung und Verwendung
US5132109A (en) * 1990-10-05 1992-07-21 Ludwig Institute For Cancer Research Method for inhibiting production of ige and method for enhancing production of igg using interleukin 9 and inhibitors thereof
DE4037837A1 (de) 1990-11-28 1992-06-04 Behringwerke Ag Zellfreie rezeptorbindungsteste, ihre herstellung und verwendung
DE4322330A1 (de) * 1992-08-31 1994-03-03 Behringwerke Ag Verwendung des IL-4-Rezeptors zur Therapie, Prophylaxe und Diagnose von allergischen, viralen, parasitären und bakteriellen Erkrankungen sowie von Pilzinfektionen
US5591825A (en) * 1994-07-05 1997-01-07 Tularik, Inc. Interleukin 4 signal transducers
US5658744A (en) * 1994-07-22 1997-08-19 The United States Of America As Represented By The Department Of Health And Human Services Methods of identifying patients having an altered immune status

Also Published As

Publication number Publication date
CA2105101C (en) 2007-10-30
MX9305269A (es) 1994-02-28
EP0585681A3 (de) 1994-10-05
EP0585681A2 (de) 1994-03-09
JPH06157335A (ja) 1994-06-03
IL106842A0 (en) 1993-12-08
ES2158852T3 (es) 2001-09-16
US6210661B1 (en) 2001-04-03
ATE202285T1 (de) 2001-07-15
US6328954B1 (en) 2001-12-11
AU668974B2 (en) 1996-05-23
NO312336B1 (no) 2002-04-29
EP0585681B1 (de) 2001-06-20
GR3036655T3 (en) 2001-12-31
DE4322330A1 (de) 1994-03-03
DK0585681T3 (da) 2001-10-01
CA2105101A1 (en) 1994-03-01
JP3703103B2 (ja) 2005-10-05
IL106842A (en) 2005-06-19
AU4495093A (en) 1994-03-10
PT585681E (pt) 2001-11-30
DE59310177D1 (de) 2001-07-26
NZ248516A (en) 1995-10-26
NO933077D0 (no) 1993-08-30

Similar Documents

Publication Publication Date Title
NO933077D0 (no) Anvendelse av il-4-reseptor for terapi i profylakse og diagnostikk av allergiske, virale og parasitiske og bakterielle sykdommer
ES2056963T3 (es) Agentes antibacterianos.
ATE190064T1 (de) Kombination therapeutische nukleoside mit weiteren therapeutisch wirksamen komponenten.
DK209088D0 (da) Medicinpraeparater, deres fremstilling og anvendelse
FI862011A0 (fi) Terapeutiska nukleosider.
NO304595B1 (no) Terapeutisk aktive derivater av 1-naftylpyrazol-3-karboksamider, farmas°ytiske preparater inneholdende dem, og mellomprodukter for fremstilling av dem
ATE81776T1 (de) Verwendung von chinolon und naphthyridinantibiotika zur herstellung von ophthalmischen arzneimitteln.
FI931204A0 (fi) Nya, saosom lipooxigenasinhibitorer verkande aminobensosultamderivat
NO991734L (no) Pyrazolinoner for behandling av potensforstyrrelser
DK99993D0 (da) Treatment and prophylaxis of diseases caused by parasites or bacteria
DK120892D0 (da) Treatment and prophylaxis of diseases caused by parasites, fungi or bacteria
NO945094L (no) Anvendelse av bradykininantagonister for fremstilling av legemidler for behandling av virussykdommer
ATE144901T1 (de) Pharmazeutische kombinationspräparate enthaltend cefotaxim und xanthinderivate und deren verwendung
ZA936350B (en) The use of IL-4 receptor for the therapy, prophylaxis and diagnosis of allergic, veral, parasitic and bacterial diseases and of fungal infections.
FI972673A7 (fi) 4,4-(disubstituoitu)sykloheksan-1-oli-monomeereja ja vastaavia yhdiste itä
DK31292D0 (da) Treatment and prophylaxis of diseases caused by parasites or bacteria
IT8719394A0 (it) Disposizione di trasferimento dipersone, in particolare per letti ospedalieri e/o simili.

Legal Events

Date Code Title Description
MK1K Patent expired